Clinicaltrialvanguard

Published October 2, 2026

Monte Rosa's MRT-8102 shows NLRP3 inflammasome activity normalization in Phase 1 study

Read the full story at Clinicaltrialvanguard

“Normalization of key pathogenic drivers” is the company's language, and the underlying biomarker data from the full press release (filed as.